



1647

BOX PATENT

Attorney Docket No. 24390

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SHINITZKY, et al.

Serial No. 09/647,457

Filed: November 29, 2000

For: ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW PEPTIDE

RECEIVED
JUL 23 2002
TECH CENTER 1600/2900

TRANSMITTAL LETTERThe Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter
- (2) Supplemental Information Disclosure Statement
- (3) Form PTO-1449 with three (3) references

Respectfully submitted,
NATH & ASSOCIATES PLLC

By:



Gary M. Nath
Registration No. 26,965
Todd L. Juneau
Registration No. 40,669
Joshua B. Goldberg
Registration No. 44,126
Customer No. 20529

Date: July 22, 2002NATH & ASSOCIATES PLLC
1030 15TH Street, NW - 6th Floor
Washington, D.C. 20005
GMN/TLJ/JBG/ls:IDS.trans

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 22 2002

In re Application of:

SHINITZKY, et al.

RECEIVED

JUL 23 2002

Serial No. 09/647,457

TECH CENTER 1600/2900

Filed: November 29, 2000

For: **ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW PEPTIDE**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTCommissioner of Patents
Washington, D.C. 20231

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. §1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

- [] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. §1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- [] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311.
- [] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311, but before payment of the issue fee.
 - [] Certification report(e) below; and
 - [] a check in the amount required by §1.17(p).
- [] d. The enclosed statement is being filed pursuant to 37 C.F.R. §1.97(i), for placement in the file.
- [x] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

#12
AB
08/01/02

[X] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[] Appropriate certification is attached.

[X] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[X] g. Copies of the documents are attached herewith with a completed Form PTO-1449.


or

[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES

By: 

Gary M. Nath
Registration No. 26,965
Todd L. Juneau
Registration No. 40,669
Joshua B. Goldberg
Registration No. 44,126
Customer No. 20529

Date: July 21, 2002
NATH & ASSOCIATES PLLC
1030 15th Street, N.W., 6th Floor
Washington, D.C. 20005
Tel. (202) 775-8383
Fax. (202) 775-8396
GMN/TLJ/JBG/ls (IDS.revisedTLJ04.08.02)

Atty Docket
24390 Serial No.
09/647,457Applicant
SHINITZKY, et al.Filing Date
Nov. 29, 2000Group Art Unit
1647

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Trans-lation
	AC						
	AD						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AE		McAleese, Sybil M., et al., "Complete amino acid sequence of the neurone-specific γ isozyme of enolase (NSE) from human brain and comparison with the non-neuronal α form (NNE)". Eur. J. Biochem, 178, 413-417 (1988).
	AF		Oliva, Daniele, et al., "Complete Structure of the Human Gene Encoding Neuron-Specific Enolase". Genomics, 10, 157-165 (1991).
	AG		Egan, Michael F., et al., "Cerebrospinal Fluid and Serum Levels of Neuron-Specific Enolase in Patients With Schizophrenia". Psychiatry Research, 43, 187-195 (1992).

Examiner _____ Date Considered _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

RECEIVED

JUL 23 2002

TECH CENTER 1600/2900